PT2877467T - 2-(azaindol-2-il)benzimidazóis como inibidores de pad4 - Google Patents

2-(azaindol-2-il)benzimidazóis como inibidores de pad4

Info

Publication number
PT2877467T
PT2877467T PT127405819T PT12740581T PT2877467T PT 2877467 T PT2877467 T PT 2877467T PT 127405819 T PT127405819 T PT 127405819T PT 12740581 T PT12740581 T PT 12740581T PT 2877467 T PT2877467 T PT 2877467T
Authority
PT
Portugal
Prior art keywords
azaindol
benzimidazoles
pad4 inhibitors
pad4
inhibitors
Prior art date
Application number
PT127405819T
Other languages
English (en)
Inventor
David Barker Michael
Liddle John
Louise Walker Ann
Matthew Wilson David
John Atkinson Stephen
Campbell Matthew
Diallo Hawa
Douault Clement
Stuart Garton Neil
John Sheppard Robert
Wellaway Christopher
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PT2877467T publication Critical patent/PT2877467T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT127405819T 2012-07-26 2012-07-26 2-(azaindol-2-il)benzimidazóis como inibidores de pad4 PT2877467T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12740581.9A EP2877467B1 (en) 2012-07-26 2012-07-26 2-(azaindol-2-yl)benzimidazoles as pad4 inhibitors
PCT/EP2012/064649 WO2014015905A1 (en) 2012-07-26 2012-07-26 2 - (azaindol- 2 -yl) benz imidazoles as pad4 inhibitors

Publications (1)

Publication Number Publication Date
PT2877467T true PT2877467T (pt) 2017-01-02

Family

ID=49996626

Family Applications (1)

Application Number Title Priority Date Filing Date
PT127405819T PT2877467T (pt) 2012-07-26 2012-07-26 2-(azaindol-2-il)benzimidazóis como inibidores de pad4

Country Status (22)

Country Link
US (4) US9127003B2 (pt)
EP (1) EP2877467B1 (pt)
JP (1) JP6063567B2 (pt)
KR (1) KR101916443B1 (pt)
CN (1) CN104470919B (pt)
AU (1) AU2012386257B2 (pt)
BR (1) BR112015001545B1 (pt)
CA (1) CA2879341C (pt)
CY (1) CY1118524T1 (pt)
DK (1) DK2877467T3 (pt)
ES (1) ES2609126T3 (pt)
HR (1) HRP20161530T1 (pt)
HU (1) HUE033294T2 (pt)
IN (1) IN2014KN02935A (pt)
LT (1) LT2877467T (pt)
PL (1) PL2877467T3 (pt)
PT (1) PT2877467T (pt)
RS (1) RS55684B1 (pt)
RU (1) RU2611010C2 (pt)
SI (1) SI2877467T1 (pt)
SM (1) SMT201700052B (pt)
WO (1) WO2014015905A1 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017014714A (es) * 2015-05-21 2018-01-25 Glaxosmithkline Ip Dev Ltd Derivados de benzoimidazol como inhibidores de peptidil arginina deiminasa 4 (pad4).
AR107032A1 (es) * 2015-12-09 2018-03-14 Padlock Therapeutics Inc Inhibidores bicíclicos de pad4
AR107030A1 (es) * 2015-12-09 2018-03-14 Padlock Therapeutics Inc Inhibidores aza-bencimidazol de pad4
CN109071497B (zh) 2016-02-23 2021-10-22 帕德罗科治疗公司 Pad4杂芳基抑制剂
CN107188867A (zh) * 2016-03-14 2017-09-22 中国科学院天津工业生物技术研究所 精氨酸脱亚氨酶4的抑制剂
CN109790162B (zh) * 2016-07-27 2022-06-28 帕德罗科治疗公司 Pad4的共价抑制剂
CN110248934B (zh) * 2016-09-12 2022-05-24 帕德罗科治疗公司 杂芳基pad4抑制剂
WO2018102262A1 (en) * 2016-12-02 2018-06-07 University Of Massachusetts Inhibitors of protein arginine deiminases (pads) and methods of preparation and use thereof
CN108689946B (zh) * 2017-04-12 2022-10-18 中国科学院上海药物研究所 2-取代硫基乙酰胺类化合物及其制备方法和应用
EP3684767B1 (en) * 2017-09-22 2024-04-24 Jubilant Epipad LLC Heterocyclic compounds as pad inhibitors
FI3697785T3 (fi) * 2017-10-18 2023-04-03 Jubilant Epipad LLC Imidatsopyridiiniyhdisteitä pad:n estäjinä
CN111386265A (zh) 2017-11-06 2020-07-07 朱比连特普罗德尔有限责任公司 作为pd1/pd-l1活化的抑制剂的嘧啶衍生物
IL274762B2 (en) 2017-11-24 2023-10-01 Jubilant Episcribe Llc Novel heterocyclic compounds as PRMT5 inhibitors
TWI762769B (zh) * 2018-02-26 2022-05-01 大陸商藥捷安康(南京)科技股份有限公司 肽醯精胺酸脫亞胺酶抑制劑及其用途
KR20200131845A (ko) 2018-03-13 2020-11-24 주빌런트 프로델 엘엘씨 Pd1/pd-l1 상호작용/활성화 억제제로서의 비사이클릭 화합물
JP7447080B2 (ja) 2018-08-08 2024-03-11 ブリストル-マイヤーズ スクイブ カンパニー Pad4阻害剤としての置換チエノピロール
CN112789087A (zh) * 2018-08-08 2021-05-11 百时美施贵宝公司 Pad酶的苯并咪唑抑制剂
BR112021002091A2 (pt) 2018-08-08 2021-05-04 Bristol-Myers Squibb Company inibidores de indol e azaindol de enzimas pad
AU2019318415A1 (en) * 2018-08-08 2021-03-25 Bristol-Myers Squibb Company Substituted benzimidazoles as PAD4 inhibitors
CN109369513B (zh) * 2018-11-20 2020-08-25 都创(上海)医药科技有限公司 一种fbdd常用分子片段的制备方法
WO2021003078A1 (en) * 2019-07-03 2021-01-07 University Of Massachusetts Inhibitors of protein arginine deiminase 1 and methods of preparation and use thereof
CN112574230B (zh) * 2019-09-27 2022-10-28 药捷安康(南京)科技股份有限公司 肽酰精氨酸脱亚胺酶抑制剂及其用途
EP4100405A1 (en) * 2020-02-06 2022-12-14 Bristol-Myers Squibb Company Macrocyclic pad4 inhibitors useful as immunosuppressant
TW202140477A (zh) * 2020-02-12 2021-11-01 美商必治妥美雅史谷比公司 雜環pad4抑制劑
CN111265526B (zh) * 2020-04-09 2021-03-19 黑龙江中医药大学 一种治疗胃癌的药物及其制备方法
AU2021265110B2 (en) 2020-04-30 2023-08-17 Gilead Sciences, Inc. Macrocyclic inhibitors of peptidylarginine deiminases
KR20230093251A (ko) 2020-09-10 2023-06-27 프리시릭스 엔.브이. Fap에 대한 항체 단편
KR20230069162A (ko) 2020-09-18 2023-05-18 스미토모 파마 가부시키가이샤 아민 유도체
WO2022140390A1 (en) 2020-12-22 2022-06-30 Gilead Sciences, Inc. Inhibitors of peptidylarginine deiminases
WO2023083365A1 (en) 2021-11-15 2023-05-19 Qilu Regor Therapeutics Inc. Pad4 inhibitors and use thereof
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
WO2023213801A1 (en) 2022-05-02 2023-11-09 Precirix N.V. Pre-targeting
WO2023230609A1 (en) * 2022-05-26 2023-11-30 Celgene Corporation Heterocyclic pad4 inhibitors
WO2024109945A1 (en) * 2022-11-24 2024-05-30 Helios Huaming Biopharma Co., Ltd. Selenium containing heterocycle compounds and use thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU570439B2 (en) 1983-03-28 1988-03-17 Compression Labs, Inc. A combined intraframe and interframe transform coding system
ES2179192T3 (es) 1995-04-14 2003-01-16 Smithkline Beecham Corp Inhibidor dosificador para albuterol.
TW533865U (en) 1997-06-10 2003-05-21 Glaxo Group Ltd Dispenser for dispensing medicament and actuation indicating device
AU752474B2 (en) * 1998-09-18 2002-09-19 Abbott Gmbh & Co. Kg 4-aminopyrrolopyrimidines as kinase inhibitors
US6315112B1 (en) 1998-12-18 2001-11-13 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6119853A (en) 1998-12-18 2000-09-19 Glaxo Wellcome Inc. Method and package for storing a pressurized container containing a drug
US6352152B1 (en) 1998-12-18 2002-03-05 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6390291B1 (en) 1998-12-18 2002-05-21 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
ES2235970T3 (es) * 1999-10-19 2005-07-16 MERCK & CO. INC. Inhibidores de tirosina quinasa.
AP1587A (en) 1999-12-24 2006-03-02 Aventis Pharma Ltd Azaindoles.
GB0115393D0 (en) 2001-06-23 2001-08-15 Aventis Pharma Ltd Chemical compounds
WO2003000690A1 (en) 2001-06-25 2003-01-03 Aventis Pharmaceuticals Inc. Synthesis of heterocyclic compounds employing microwave technology
CN1901958B (zh) 2003-11-03 2011-03-09 葛兰素集团有限公司 流体分配装置
CA2546192C (en) 2003-11-17 2010-04-06 Pfizer Products Inc. Pyrrolopyrimidine compounds useful in treatment of cancer
FR2862971B1 (fr) * 2003-11-28 2006-03-24 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
US7429611B2 (en) * 2004-09-23 2008-09-30 Bristol-Myers Squibb Company Indole inhibitors of 15-lipoxygenase
EP2205085A1 (en) * 2007-09-25 2010-07-14 Merck Sharp & Dohme Corp. 2-aryl or heteroaryl indole derivatives
CA2723279A1 (en) 2008-05-28 2009-12-23 Wyeth Llc 3-substituted-1h-indole compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
RU2011106786A (ru) * 2008-07-23 2012-08-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) Ингибиторы пиразолопиридинкиназы
JP5680054B2 (ja) * 2009-04-02 2015-03-04 メルク セローノ ソシエテ アノニム ジヒドロオロテート脱水素酵素阻害剤
WO2010118208A1 (en) 2009-04-09 2010-10-14 Exelixis, Inc. Benzoxazepin-4- (5h) -yl derivatives and their use to treat cancer

Also Published As

Publication number Publication date
US20150175600A1 (en) 2015-06-25
JP2015522628A (ja) 2015-08-06
SI2877467T1 (sl) 2017-02-28
US9833449B2 (en) 2017-12-05
CA2879341A1 (en) 2014-01-30
US9127003B2 (en) 2015-09-08
CA2879341C (en) 2019-06-11
CN104470919A (zh) 2015-03-25
WO2014015905A1 (en) 2014-01-30
AU2012386257B2 (en) 2016-09-08
BR112015001545B1 (pt) 2022-07-05
CY1118524T1 (el) 2017-07-12
US9518054B2 (en) 2016-12-13
RU2014152456A (ru) 2016-09-20
RS55684B1 (sr) 2017-07-31
US10039755B2 (en) 2018-08-07
EP2877467B1 (en) 2016-11-02
BR112015001545A2 (pt) 2017-07-04
IN2014KN02935A (pt) 2015-05-08
EP2877467A1 (en) 2015-06-03
CN104470919B (zh) 2016-07-06
ES2609126T3 (es) 2017-04-18
KR101916443B1 (ko) 2018-11-08
HRP20161530T1 (hr) 2017-02-10
SMT201700052B (it) 2017-03-08
KR20150038438A (ko) 2015-04-08
HUE033294T2 (en) 2017-11-28
AU2012386257A1 (en) 2015-03-12
LT2877467T (lt) 2017-01-10
US20170119750A1 (en) 2017-05-04
RU2611010C2 (ru) 2017-02-17
PL2877467T3 (pl) 2017-08-31
JP6063567B2 (ja) 2017-01-18
DK2877467T3 (en) 2017-02-13
US20160009716A1 (en) 2016-01-14
US20180161316A1 (en) 2018-06-14

Similar Documents

Publication Publication Date Title
HRP20181429T1 (hr) Novi derivati benzimidazola kao inhibitori kinaze
SI2877467T1 (sl) 2-(azaindol-2-il)benzimidazoli kot PAD4 inhibitorji
HK1210775A1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
EP2890691A4 (en) BENZIMIDAZOLE DERIVATIVES AS ITK INHIBITORS
RS58892B1 (sr) Jedinjenja 3-aminocikloalkila kao inhibitori ror-gama-t i njihove upotrebe
HK1211027A1 (en) Pyrrolotriazinone derivatives as pi3k inhibitors pi3k
ME02576B (me) Derivati tetrahidropirolotiazina kao inhibitori bace
HK1207366A1 (en) Thiadiazolidinediones as gsk-3 inhibitors gsk-3
ZA201409497B (en) Tetrahydroquinazolinone derivatives as parp inhibitors
HK1209422A1 (en) Fbxo3 inhibitors fbxo3
EP2866893A4 (en) HETEROCYCLIC GUANIDINE F1FO ATPASE INHIBITORS